(Boursier.com) — Valbiotis announced the signature of a research partnership in the intestinal microbiota with the MEDIS Unit of Clermont Auvergne University. The research project will focus on the active substances TOTUM 070 and TOTUM 448 developed by Valbiotis against dyslipidemia and metabolic damage to the liver. It will be partly funded by the National Research Agency to the tune of 363,000 euros.
Led by a joint laboratory for both entities, the MIMETiv project will aim to develop a complete and dynamic human gastrointestinal model integrating the microbiota of the small intestine for the first time. This model will make it possible to obtain exclusive data on the effects and modes of action of the active plant substances of Valbiotis at the intestinal level, within the framework of non-drug strategies for the fight against metabolic and cardiovascular diseases.
©2022 Boursier.com